All articles by GlobalData Healthcare

  1. FibroGen’s pamrevlumab trial may have too few participants

    FibroGen’s Phase III trial with FG-3019 (pamrevlumab) for idiopathic pulmonary fibrosis (IPF) may face challenges enrolling patients since it does not…
    Read More…

    19 Jun
  2. Abbvie dominates Hidradenitis Suppurativa market despite room for new biologics

    On 5 June, InflaRx announced top-line Phase IIb results for IFX-1 in hidradenitis suppurativa (HS). However, IFX-1 did not demonstrate…
    Read More…

    19 Jun
  3. Brodalumab shows promise in Axial Spondyloarthritis with strong Phase III results

    Trial results for Kyowa Hakko Kirin’s 16-week Phase III study testing the safety and efficacy of brodalumab, an interleukin 17…
    Read More…

    18 Jun
  4. As small molecules continue to dominate industry approvals, API manufacturing rises in importance

    Small molecule drugs continue to dominate approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency…
    Read More…

    5 Jun
  5. Medicines for rare diseases have seen an uptake in EMA orphan designations

    The European Medicines Agency (EMA) 2018 annual report has revealed that over the last five years the number of successful…
    Read More…

    4 Jun
  6. Positive data for Promedior’s PRM-151 boost development efforts in IPF

    At the recently concluded 2019 American Thoracic Society International Conference (ATS), Promedior unveiled positive long-term safety and efficacy Phase II…
    Read More…

    4 Jun
  7. Myovant reports positive relugolix data but faces stiff competition from rivals AbbVie and ObsEva

    On 14 May Myovant Sciences reported positive data from LIBERTY-1, the first of two Phase III studies of its oral…
    Read More…

    4 Jun
  8. Could safer CAR-T therapies be right around the corner?

    CAR-T therapy is generally viewed as a promising approach for the treatment of particular cancers. However, several factors adversely affect…
    Read More…

    4 Jun
  9. HER2+ breast cancer Phase II benchmarking

    Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20–30% of breast cancer tumours and is associated with a…
    Read More…

    4 Jun
  10. WHO adopts resolution to expand access to medicine by improving pricing transparency

    On the final day of the 72nd session of the World Health Assembly (WHA), the World Health Organisation (WHO) has…
    Read More…

    4 Jun
Close
Close
Close

Go Top